Zydus receives approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets

Ahmedabad, 24 November, 2017

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the final approval from the USFDA to market Minocycline Hydrochloride Extended-Release Tablets in strengths of 45 mg, 80 mg, 90 mg, 105 mg, and 135 mg. Zydus also received the tentative approval for Minocycline Hydrochloride Extended-Release Tablets, 55 mg, 65 mg, and 115 mg.

Minocycline Hydrochloride Extended-Release Tablets are a tetracycline-class drug, indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***